Home
Live Updates
Johnson & Johnsons nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN) : comparemela.com
Johnson & Johnson's nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN)
/PRNewswire/ -- Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for...
Related Keywords
Texas ,
United States ,
American ,
Prnewswire Johnson ,
Bridget Kimmel ,
Katie Abouzahr ,
Drug Administration ,
Exchange Commission ,
Hematology Am Soc Hematol Educ Program ,
Janssen Research Development ,
Janssen Biotech Inc ,
None Of The Janssen Pharmaceutical Companies ,
Johnson ,
National Library Of Medicine ,
Janssen Pharmaceutical Companies ,
Fetal Medicine Foundation World Congress ,
Breakthrough Therapy Designation ,
Vice President ,
Maternal Fetal Immunology Disease Area Leader ,
Fast Track ,
European Medicines Agency ,
American Journal ,
Rare Autoantibody ,
Maternal Fetal ,
Prevalent Rheumatology ,
Innovative Medicine ,
Janssen Biotech ,
Private Securities Litigation Reform Act ,
Janssen Research ,
Annual Report ,
Note Regarding Forward Looking ,
Quarterly Reports ,
Hemolytic Diseases ,
Pregnant Women ,
High Risk ,
Early Onset Severe Hemolytic Disease ,
Pregnant Individuals ,
Oral Presentation ,
Expert Review ,
Johnson Amp ,
comparemela.com © 2020. All Rights Reserved.